Edwards Lifesciences - EW Forward P/S Multiple
Edwards Lifesciences' leadership in the development of cardiac systems and its robust R&D drive the price action. On the GURU.Markets platform, the company's expected P/S illustrates market expectations, where the value 4.80 describes the current level. Simultaneously, the business is implementing strict raw material certification to reduce toxic emissions and is transitioning to eco-packaging using renewable energy at its plants.
Edwards Lifesciences Inc. (EW) - metric breakdowns and financial figures
- current price and projected stock value:
- issuer market value details:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Edwards Lifesciences|EW - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Edwards Lifesciences|EW - Aggregate Debt Obligations|Debts to Book Capitalization Edwards Lifesciences Inc.|EW - Long-Term Debt|Company Short-Term Debt Edwards Lifesciences|Quick Liquidity Indicator edwards.com
- financial results and valuation multiples details:
EW - Net Profit|Projected Future Earnings Edwards Lifesciences|EW - Business Payback Period|Future Price to Earnings Edwards Lifesciences Corp|EW - Market Cap to Earnings and Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Edwards Lifesciences Inc.|EW - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Edwards Lifesciences|EW - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months edwards.com|EW - Earnings per share growth this year|Expected earnings per share growth for next year Edwards Lifesciences
- sales and revenue data:
Summary company analysis:Edwards Lifesciences Corporation EW
The market values Edwards Lifesciences (EW) as a high-tech leader with premium growth potential. The company's expected P/S ratio compares current market capitalization with projected revenue, determining the fair value of future sales flows. This chart confirms the valuation's resilience, as inelastic demand for unique TAVR systems allows the business to maintain high pricing power, transforming the asset into a defensive tool with a high-quality fundamental profile.
Competitor analysis
Forward P/S Multiple BSX (Boston Scientific Corporation)|RMD: Market Cap to Projected Revenue|OmniPod - Forward P/S Multiple|Market Cap to Expected Sales Ratio Zimmer Biomet Holdings ZBH|COO: Forward P/S Multiple|Forward Price-to-Revenue Multiple aligntech.com|GMED (Globus Medical) - Forward P/S Multiple|Forward P/S Multiple TransMedics Group Inc|Price-to-Projected Revenue Ratio ATEC Spine (ATEC)|Price-to-Projected Revenue Ratio AORT (Artivion Corp)|Enovis Corporation - Forward Price-to-Revenue Multiple|Forward Price to Sales IART|Establishment Labs Holdings Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Beta Bionics, Inc.|Iradimed (IRMD) - Price-to-Projected Revenue Ratio|Projected Price to Revenue Embecta Health EMBC|Forward Price-to-Revenue Multiple TNDM|Forward P/S Multiple axogeninc.com|Forward P/S Multiple SIBN|Market Cap to Expected Sales Ratio Orthofix Medical|Price-to-Projected Revenue Ratio Bioventus Corp BVS|KIDS (OrthoPediatrics Corp) - Future Price to Revenue|TMCI - Price-to-Projected Revenue Ratio|blade.com (SRTA) - Forward Price-to-Revenue Multiple|CARL: Forward P/S Multiple|Market Cap to Future Revenue Ratio RxSight Inc (RXST)|Price-to-Projected Revenue Ratio ClearPoint Neuro Inc.|Market Cap to Projected Revenue STXS (Stereotaxis Corporation)|Forward Price-to-Revenue Multiple STIM (Neuronetics, Inc.)|Price to Expected Revenue Ratio SGHT|Forward P/S Multiple OBIO (Orchestra BioMed, Inc.)|Anika Therapeutics Inc. (ANIK) - Market Cap to Future Revenue Ratio|InspireMD Corp - Forward P/S Multiple|ZJYL (Jin Medical International) - Market Cap to Projected Revenue|VANI (vivani.com) - Forward Price-to-Revenue Multiple|Forward Price-to-Revenue Multiple Xtant Medical|NMTC (NeuroOne Medical Technologies Corporation) - Forward P/S Multiple|Forward P/S Multiple Modular Med|Price-to-Projected Revenue Ratio Myomo, Inc (MYO)|COCH (Envoy Medical Inc) - Forward Price to Sales|Forward P/S Multiple VVOS (Vivos Therapeutics)|NVNO: Market Cap to Projected Revenue|SINT - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Tenon Medical Inc. TNON|LFWD (ReWalk Robotics Ltd) - Forward Price-to-Revenue Multiple|Autonomix Medical - Forward Price to Sales|Price-to-Projected Revenue Ratio INVO Fertility Inc|Price-to-Projected Revenue Ratio BBLG|Forward P/S Multiple AXNX|Market Cap to Expected Sales Ratio BIOLASE Inc.|Forward P/S Multiple DYNT (Dynatronics)|FNA (Paragon 28 Inc.) - Future Price to Revenue|INVO Bio - Forward P/S Multiple
